Dr. Muffly on the Evaluation of Briquilimab Conditioning Prior to HSCT in AML

Lori Muffly, MD, associate professor of Medicine, Blood and Marrow Transplantation and Cellular therapy, Stanford Health Care, discusses the clinical outcomes with the use of a novel conditioning regimen featuring the anti-CD117 monoclonal antibody briquilimab (formerly JSP191) plus low-dose irradiation and fludarabine prior to allogeneic hemopoietic stem cell transplant (HSCT) in older patients with acute myeloid leukemia (AML).

In a subanalysis of a single-center phase 1 trial (NCT04429191), investigators examined this novel HSCT conditioning in a group of 12 patients 60 years of age or older with AML. Data presented at the 2023 Transplantation and Cellular Therapy Meetings showed that 9 patients had measurable residual disease (MRD) prior to HSCT, Muffly begins. At 1 year following HSCT, 6 of the 9 MRD-positive patients at baseline achieved MRD clearance, and the median time to MRD clearance was 90 days. Moreover, at 1 year, 67% of patients were alive and MRD negative, Muffly notes. The 1-year overall survival (OS) rate for all patients was 75%, and the 1-year relapse-free survival rate was 67%, Muffly says.

Investigators concluded that briquilimab plus low-dose irradiation and fludarabine demonstrated predictable clearance that allowed for safe and effective donor cell infusion between 9 and 14 days following briquilimab, Muffly concludes.